TY - JOUR
AU - Nora Franzen
AU - Wim H. van Harten
AU - Valesca P. Retèl
AU - Peter Loskill
AU - Janny van den Eijnden-van Raaij
AU - Maarten IJzerman
AB - Healthcare systems are faced with the challenge of providing innovative treatments, while shouldering high drug costs that pharmaceutical companies justify by the high costs of R&D. An emergent technology that could transform R&D efficiency is organ-on-a-chip. The technology bridges the gap between preclinical testing and human trials through better predictive models, significantly impacting R&D costs. Here, we present an expert survey on the future role of organ-on-a-chip in drug discovery and its potential quantitative impact. We find that the technology has the potential to reduce R&D costs significantly, driven by changes in direct costs, success rates and the length of the R&D process. Finally, we discuss regulatory challenges to efficiency improvements.
BT - Drug Discovery Today
DA - 2019-09-01
DO - 10.1016/j.drudis.2019.06.003
IS - 9
LA - en
N2 - Healthcare systems are faced with the challenge of providing innovative treatments, while shouldering high drug costs that pharmaceutical companies justify by the high costs of R&D. An emergent technology that could transform R&D efficiency is organ-on-a-chip. The technology bridges the gap between preclinical testing and human trials through better predictive models, significantly impacting R&D costs. Here, we present an expert survey on the future role of organ-on-a-chip in drug discovery and its potential quantitative impact. We find that the technology has the potential to reduce R&D costs significantly, driven by changes in direct costs, success rates and the length of the R&D process. Finally, we discuss regulatory challenges to efficiency improvements.
PY - 2019
SP - 1720
EP - 1724
T2 - Drug Discovery Today
TI - Impact of organ-on-a-chip technology on pharmaceutical R&D costs
UR - https://www.sciencedirect.com/science/article/pii/S135964461930042X
VL - 24
Y2 - 2023-05-26
SN - 1359-6446
ER -